Item Posts Archive - Page 43 of 1770 - Medivizor
Navigation Menu

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Posted by on Nov 14, 2022 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of pertuzumab (Perjeta) and trastuzumab (Herceptin) combined therapy with trastuzumab alone in patients with HER2-positive (HER2+) advanced breast cancer (BC). The study found that the combined therapy was more effective and well tolerated compared to single therapy in...

Read More

Comparing salvage and primary holmium laser enucleation of the prostate in patients with benign prostatic hyperplasia.

Comparing salvage and primary holmium laser enucleation of the prostate in patients with benign prostatic hyperplasia.

Posted by on Nov 5, 2022 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study compared the safety and effectiveness of salvage (S) and primary (P) holmium laser enucleation of the prostate (HoLEP) in patients with benign prostatic hyperplasia (BPH). It also evaluated what were the procedures leading to S-HoLEP in these patients. The authors concluded that S-HoLEP was similar to...

Read More

Is dorzagliatin an effective add-on treatment to metformin in patients with type 2 diabetes?

Is dorzagliatin an effective add-on treatment to metformin in patients with type 2 diabetes?

Posted by on Nov 5, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effectiveness and safety of adding dorzagliatin (HMS552) to metformin therapy in patients with type 2 diabetes (T2D) with inadequately controlled blood glucose (sugar) while using metformin (Glucophage) alone. The data showed effective blood glucose control, good tolerance, and safety in patients...

Read More

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Posted by on Oct 25, 2022 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of tebentafusp (Kimmtrak) in patients with metastatic uveal melanoma who had received previous treatments. The study found that tebentafusp had promising effectiveness and a good safety profile in these patients. Some background Uveal melanoma is a rare and aggressive eye tumor....

Read More